» Articles » PMID: 18273863

Increased Oxidative Stress in Cirrhotic Rat Livers: A Potential Mechanism Contributing to Reduced Nitric Oxide Bioavailability

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2008 Feb 15
PMID 18273863
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: In cirrhotic livers, decreased nitric oxide (NO) bioavailability is a major factor increasing intrahepatic vascular tone. In several vascular disorders, an increase in superoxide (O(2) (-)) has been shown to contribute to reduced NO bioavailability through its reaction with NO to form peroxynitrite. This study was aimed to test the hypothesis that, in cirrhotic livers, increased O(2) (-), by reacting with NO, reduces NO bioavailability. In control and cirrhotic rat livers, NO bioavailability was evaluated by the measurement of cyclic guanosine monophosphate in liver tissue and by 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF-FM-DA) fluorescence in isolated sinusoidal endothelial cells (SEC); the O(2) (-) content was determined by dihydroethidium staining in fresh liver sections. In addition, the role of endothelial nitric oxide synthase (eNOS), xanthine oxidase (XO), and cyclooxygenase (COX) as possible sources of O(2) (-) and the role of superoxide dismutase (SOD) enzymatic activity as an O(2) (-) scavenger were determined in liver homogenates. Protein-nitrotyrosination, a marker of the NO-O(2) (-) reaction, was evaluated in liver homogenates. Furthermore, in control SEC and bovine aortic endothelial cells, NO modulation by O(2) (-) was evaluated. Cirrhotic livers exhibited increased O(2) (-) levels. This was due, at least in part, to increased production by COX and XO but not eNOS and to reduced scavenging by SOD. Increased O(2) (-) was associated with a significant reduction in NO bioavailability and increased nitrotyrosinated proteins. In endothelial cells, an inverse relationship between O(2) (-) levels and NO bioavailability was observed.

Conclusion: Our data show that oxidative stress may contribute to reduced NO bioavailability in cirrhotic livers, supporting the evaluation of O(2) (-) reduction as a potential mechanism to restore NO content.

Citing Articles

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M, Buldak L Metabolites. 2025; 15(2).

PMID: 39997697 PMC: 11857179. DOI: 10.3390/metabo15020072.


Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells.

Akkiz H, Gieseler R, Canbay A Int J Mol Sci. 2024; 25(14).

PMID: 39063116 PMC: 11277292. DOI: 10.3390/ijms25147873.


Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats.

Asada S, Kaji K, Nishimura N, Koizumi A, Matsuda T, Tanaka M Cells. 2024; 13(6.

PMID: 38534382 PMC: 10968969. DOI: 10.3390/cells13060538.


Mechanobiology of portal hypertension.

Felli E, Selicean S, Guixe-Muntet S, Wang C, Bosch J, Berzigotti A JHEP Rep. 2023; 5(11):100869.

PMID: 37841641 PMC: 10568428. DOI: 10.1016/j.jhepr.2023.100869.


Deciphering Molecular Mechanisms of Carbon Tetrachloride- Induced Hepatotoxicity: A Brief Systematic Review.

Fareed M, Khalid H, Khalid S, Shityakov S Curr Mol Med. 2023; 24(9):1124-1134.

PMID: 37818557 DOI: 10.2174/0115665240257603230919103539.